Laura Bao

Hematóloga en el CHUS

Cute but will fight

[Valentín Ortiz-Maldonado @ValentinOrtizMD]

Can early CAR T-cell redosing improve the therapeutic index of CAR T-cell therapy?

Our study, now published in @Haematologica, suggests that an early (day +14) second CD19 CAR T-cell infusion may increase CAR T-cell exposure, prolong persistence, and improve response durability.

[GELTAMO @geltamo]

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study - The Lancet Haematology https://t.co/rxq2oO0dQw

[Jose Gomez Rial @gomez_rial5]

Frente a quienes actúan con irresponsabilidad, es necesario plantar cara y defender con rigor el sistema de trasplantes que salva vidas cada día.

Gracias a @elconfidencial por darme voz. Pido difusión para que la verdad llegue más lejos que el ruido.

https://t.co/CTViWTSfTb

[Alex Rampotas @ARampotas]

What a great meeting it has been #cart26 !

Many congratulations to the wonderful scientific committee led by @AnnalisaRugger1 and @MariaThemeli1 for a superb programme and everyone involved for the delivery of the meeting!

Fantastic keynotes but more importantly a fantastic set of abstracts of novel research that shows that CAR-T research is ever growing

From haematological cancers to autoimmune diseases and solid tumours, CAR T cell therapies and their close cousins (NKs, γδ) have the potential to transform medicine. Future will be bright and exciting! See you all soon

[Valentín Ortiz-Maldonado @ValentinOrtizMD]

🚨New in Lancet Haematology:

CART19-BE-02 reports the multicentre phase 2 trial of varnimcabtagene autoleucel (var-cel), a hospital-based, point-of-care CD19 CAR T for adults with R/R B-cell precursor ALL.

https://t.co/OD0Q3M98Ud

🔓Free access link:
https://t.co/p3O7qOLrlm

[ADOS @doadoressangue]

O mellor agasallo que alguén pode ter este día é A VIDA
👑 Fai de Rei e #doasangue
Estarás facendo o mellor regalo do mundo: A VIDA
Grazas!

[Sam Yamshon @samyamshon]

Dr @CaitieGribbinMD presented incredibly data on the role of follicular dendritic cells and the temporal relationship with FL progression… with actionable targets! Incredible and provocative work, we’re excited to have her join our faculty! @WCMHemOncFellow @WCMLymphoma #ASH24

[GELTAMO @geltamo]

Testicular large B‐cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL - Rivas‐Delgado - 2024 - HemaSphere - Wiley Online Library https://t.co/hNwcQRhVON

[Izaskun Zeberio @ixazebe]

Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on behalf of The American Society of Transplantation and Cellular Therapy and the EBMT https://t.co/BiZigV7BUW

[Julio Delgado @JulioDelgadoHem]

Today, at TLH, we summarise a decade of hard work. We wish to thank all colleagues, patients and relatives, who helped us during this amazing journey.
https://t.co/CIzVqbLH3m

[@sehh_es @sehh_es]

📢 Mesa debate "CLAVES en Linfoma del Manto" con las principales novedades presentadas en #EHA2024.

📅Jueves 27 de junio
⏰18:00h
👩‍⚕️👨‍⚕️Moderan @amniebla y @DrRaulCordoba
👀Síguelo en #HemoTube: https://t.co/pKhiuamRdn

#CLAVESenLCM #linfoma #SEHHContigo #SEHHematología

[Redacción Médica @redaccionmedica]

🏥El Clínic de Barcelona empieza a ofrecer #CAR-T de forma ambulatoria para #pacientes que se encuentren en buen estado
https://t.co/ydv7S6FA9r

[Adrián Mosquera Orgueira @MosqueraOrgeira]

During #EHA24, visit our poster on machine-learning for predicting duration of response to #belamaf monotherapy using #baseline #data in R&R #Myeloma. Don't miss it! @mvmateos @MSoniaGlez https://t.co/E7IHM1hEOD

[British Journal of Haematology @BrJHaem]

Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease
https://t.co/12VuWEQ3R0

[Adrián Mosquera Orgueira @MosqueraOrgeira]

Very happy to have validated the NGS-free machine learning-driven risk model #AIPSS-MDS in #CMML. @gesmd @dvalcarcel @Wang_Yu_Hung

[Adrián Mosquera Orgueira @MosqueraOrgeira]

@Laubaoper discusses new treatment paradigms in #Hodgkin #Lymphoma in #Gijon #Spain

[Carlos Fernandez de Larrea @fdezdelarrea]

Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma https://t.co/sx8x9di0eL

[Valentín Ortiz-Maldonado @ValentinOrtizMD]

11:25

Gonzalo Calvo @hospitalclinic: The (invaluable) Role of Hospital Exemption for ATMPs in the EU. #CART24 @TheEBMT
@EHA_Hematology

[Jordan Gauthier @drjgauthier]

FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies https://t.co/Zebpq3kQKx

[Valentín Ortiz-Maldonado @ValentinOrtizMD]

Although CRS/ICANS still seem to get most of the attention, it's infections that remain one of the main causes of morbidity and mortality after CAR T cell therapy.

Here some insights on this matter by the our dearest @NicoleGarciaP 💪💫 @hospitalclinic
https://t.co/R2snU4Vk63